Antiplatelets for Psoriasis

MG
SB
Overseen BySarah Boyce
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: NYU Langone Health
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory/pro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.

Who Is on the Research Team?

MG

Michael Garshick, MD

Principal Investigator

NYU Langone Health

Are You a Good Fit for This Trial?

This trial is for adults with psoriasis, including those with palmoplantar pustulosis or psoriatic arthritis. Participants should not have conditions that would make aspirin or clopidogrel unsafe for them.

Inclusion Criteria

English-speaking unless a translated informed consent form is approved
Able and willing to provide written informed consent for the study
I am between 18 and 89 years old.
See 2 more

Exclusion Criteria

Anemia with hemoglobin < 9 mg/dl or thrombocytopenia with platelet count < 75 or thrombocytosis with platelet count > 600
History of severe bleeding or bleeding disorders
I am currently being treated for active cancer.
See 12 more

What Are the Treatments Tested in This Trial?

Interventions

  • Aspirin
  • Clopidogrel

Trial Overview

The study compares the effects of two antiplatelet drugs, aspirin and clopidogrel, versus a placebo on blood vessel inflammation in people with psoriasis. Participants are randomly assigned to one of the three groups.

How Is the Trial Designed?

6

Treatment groups

Experimental Treatment

Group I: Placebo, then Clopidogrel, then AspirinExperimental Treatment3 Interventions
Group II: Placebo, then Aspirin, then ClopidogrelExperimental Treatment3 Interventions
Group III: Clopidogrel, then Placebo, then AspirinExperimental Treatment3 Interventions
Group IV: Clopidogrel, then Aspirin, then PlaceboExperimental Treatment3 Interventions
Group V: Aspirin, then Placebo, then ClopidogrelExperimental Treatment3 Interventions
Group VI: Aspirin, then Clopidogrel, then PlaceboExperimental Treatment3 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

NYU Langone Health

Lead Sponsor

Trials
1,431
Recruited
838,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+